Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04261439
Title A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

skin melanoma

Advanced Solid Tumor

lymphoma

Therapies

NIZ985

NIZ985 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL


No variant requirements are available.